The Island Capsule is a publication of the PEI College of Pharmacy and is forwarded to every registrant of the College on the 1st and 3rd Fridays of the month.
Standardization of Colonoscopy Preparation
The PEICP is sharing a communication from Health PEI regarding the standardization of colonoscopy prep.
Health PEI and the Colorectal Cancer Screening Program have been working to improve coordination and access to cancer screening colonoscopies.
Beginning in early July, the CRC Screening Program will be piloting a diagnostic navigation program. During this pilot, the diagnostic navigation program will recruit patients from the Colorectal Cancer Screening Program with a positive Fecal Immunochemical Test (FIT). The navigation team will direct and support these patients by providing telephone health assessments, bowel preparation and procedure information and a colonoscopy appointment if appropriate. The primary goal of the navigation program is to meet the national target of having 90% of FIT-positive patients receive a colonoscopy procedure within 60 days of an abnormal fecal test result.
A patient in the navigation program will complete one of three bowel preparations. For a standard bowel preparation, the patient will purchase one box of Bi-Peglyte (no substitutions); the box includes (2) sachets to make (2) litres of Bi-peglyte and (3) Bisacodyl tablets. For an extended bowel preparation, the patient will purchase two boxes of Bi-Peglyte (no substitutions). Patients with an allergy or intolerance to polyethylene glycol will complete a Pico-Salax bowel preparation, buying one box of Pico-Salax.
For patients to easily access these bowel cleansing products, please consider ordering to ensure the product is available in your pharmacy. To assist your staff in answering patient questions about the bowel preparations, we have posted them online at https://src.healthpei.ca/colorectal-cancer-screening.
If you have any questions, please call 1-855-733-0762 to speak with a member of the navigation program team or email firstname.lastname@example.org
Health Canada Updated Resources- Infant Formula Shortage
Health Canada has published an updated version of the Information to help guide families during the shortage of hypoallergenic infant formula fact sheet. The updated fact sheet now includes a section on speaking with a pharmacist, to provide clear direction on what Canadian families and caregivers need to do to access hypoallergenic formula. The fact sheet also includes a description of infant formulas affected by the shortage, tips about what to do during the shortage, a recommendation to speak to a healthcare provider, and useful information on possible alternative approaches and products.
Dalhousie Pharmacy Endowment Fund-Deadline
Pharmacists living in the Maritime Provinces and faculty members of the College of Pharmacy, Dalhousie University are eligible to apply to receive funding to support the development/implement programs of benefit to pharmacy practice and/or research.
Please be reminded of the following important date for submission of the Letter of Intent to apply for a grant from Dalhousie Pharmacy Endowment Fund in the 2022-23 competition.
SEPTEMBER 1ST 2022-Applicants are required to submit a summary of no more than one page, describing the subject matter of the grant proposal to be submitted, due one month prior to the application deadline.
The letter of intent, due on September 1st can be sent electronically to email@example.com. Paper copies are not required.
The Dalhousie Pharmacy Endowment Fund was established in 1988 to provide financial support to programs of mutual interest and benefit to both the profession and the College of Pharmacy. More information about the Fund and the application process can be found at https://www.dal.ca/faculty/health/pharmacy/research/endowment-fund.html or feel free to contact me at any time.
CCCEP Introduces New Blog
The Canadian Council on Continuing Education in Pharmacy (CCCEP) recently partnered with an external provider to develop an educational outreach strategy for various stakeholders. CCCEP is pleased to release its first article - Today’s Pharmacy Professional: Meeting Career Demands Through Continuing Education - in a series of articles about the value of high-quality continuing education for pharmacy professionals, the difference it can make to their practice and careers, and the role accreditation can play in ensuring the quality of continuing education.
National Drug Schedules-Final Recommendations for topical diclofenac dietheylamine
The interim recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on June 5, 2022, that:
Diclofenac diethylamine – for human use - when sold as a single medicinal ingredient for topical use on the skin in concentrations greater than 1.16% and less than or equal to 2.32% for not more than 7 days - in package sizes containing greater than 2.6g of diclofenac diethylamine be granted Schedule III status
Diclofenac diethylamine – for human use - when sold as a single medicinal ingredient for topical use on the skin in concentrations greater than 1.16% and less than or equal to 2.32% for not more than 7 days - in package sizes containing no more than 2.6g of diclofenac diethylamine be granted Unscheduled status
Diclofenac diethylamine – for human use - when sold as a single medicinal ingredient for topical use on the skin in concentrations of not more than 1.16% for not more than 7 days remain Unscheduled
were finalized effective July 26, 2022. Final approval of the interim recommendations was made by NAPRA’s Board of Directors, in consideration of comments received during the 30-day review period. The National Drug Schedules will be revised accordingly.
Visiting the PEICP Office
If you need to visit the College office, please email firstname.lastname@example.org or call 902-628-3561 to make an appointment.